Retatrutide

Also known as: LY3437943, Triple G

Weight LossPHASE 3

Clinical Status

Phase 3 Clinical Trials — NDA expected 2026.

Mechanism of Action

Activates three receptors: GLP-1, GIP, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects.

Dosing Defaults

Dose

4-12 mg weekly

Frequency

Once weekly

Administration

Subcutaneous injection weekly

Timing

Morning, same day each week

Food

with or without

Duration

Long-term use expected

Dose range: 1-12 mg weekly

Weekly injection — titrate slowly over weeks.

Side Effects

•Nausea
•Diarrhea
•Vomiting
•Constipation
•Heart rate increases
•Pancreatitis (rare)

Contraindications & Warnings

•Not medical advice
•Currently in Phase 3 trials

Compare

Compare Retatrutide with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Retatrutide dose.

Open Calculator

Related Weight Loss Peptides

Semaglutide

FDA APPROVED

Weight Loss

GLP-1 receptor agonist. FDA-approved for type 2 diabetes and weight management.

Tirzepatide

FDA APPROVED

Weight Loss

Dual GLP-1/GIP receptor agonist. FDA-approved for T2D and weight management.

AOD-9604

PHASE 2

Weight Loss

GH fragment for fat metabolism. Does NOT produce typical HGH side effects.

Liraglutide

FDA APPROVED

Weight Loss

Daily GLP-1 agonist. FDA-approved for both diabetes and weight management.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.